# Lixisenatide (Adlyxin)

> Short-acting GLP-1 agonist focused on postprandial glucose.

Source: https://peptides.cafe/peptide/lixisenatide
Category: GLP-1 Agonist · Metabolic
Tag: FDA-Approved · Metabolic

## Mechanism
Exendin-4 derivative with potent postprandial glucose-lowering effect via delayed gastric emptying and enhanced insulin response.

## Research areas
- Type 2 diabetes
- Postprandial hyperglycemia

## Common research protocols
- Daily: 10 mcg SC daily x14d, then 20 mcg daily.

## Study summaries
- "ELIXA trial" — NEJM (2015): Cardiovascular safety in T2D patients post-ACS.

## Considerations
- FDA-approved.
- GI side effects common.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.